ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Celltrion's coronavirus drug shows promise in animal tests

South Korean pharmaceutical records 100-fold viral load reduction

The company said the pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine.  (Photo courtesy of Celltrion) 
JADA NAGUMO, Nikkei staff writer | South Korea

TOKYO -- South Korean drugmaker Celltrion has recorded positive preclinical results for its coronavirus treatment, the company announced on Monday.

The pharmaceutical group said the experimental drug, which assessed efficacy in animals, demonstrated a 100-fold reduction in the viral load of COVID-19.

Read Next

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close